Screener / SEC EDGAR /CIK 0001088856 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Corcept Therapeutics Inc CORT

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 24, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

20.3% to 5.9% (-14.4 pts)

The MD&A has no sentence that names a cause for this change.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-29.4%

The MD&A has no sentence that names a cause for this change.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-28.4%

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+12.8%

“The increase of cost of sales as a percentage of revenue for the year ended December 31, 2025 compared to 2024 was primarily due to a decrease in the average selling price of our Products.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +12.8%

    “The increase of cost of sales as a percentage of revenue for the year ended December 31, 2025 compared to 2024 was primarily due to a decrease in the average selling price of our Products.”

    Read it in the FY 2025 10-K
  • FY 2024 +39.9%

    “Higher sales volume accounted for 79.4 percent of the increase for the year ended December 31, 2024, with the remaining growth due to a price increase effective January 1, 2024.”

    Read it in the FY 2024 10-K

    “The increase of cost of sales as a percentage of revenue for the year ended December 31, 2024 compared to 2023 was primarily due to increased manufacturing and distribution costs.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 -14.4 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 -2.0 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Net income

0 of 2 years explained
  • FY 2025 -29.4%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +33.0%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

0 of 2 years explained
  • FY 2025 -28.4%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +55.9%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.